HER2 Overexpression in Periampullary Tumors According to Anatomical and Histological Classification—A Systematic Review
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 2010, 362, 1605–1617. [Google Scholar] [PubMed]
- Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2012, 62, 10–29. [Google Scholar] [CrossRef] [PubMed]
- Lowenfels, A.B.; Maisonneuve, P. Epidemiology and risk factors for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006, 20, 197–209. [Google Scholar] [CrossRef]
- Koorstra, J.B.; Hustinx, S.R.; Offerhaus, G.J.; Maitra, A. Pancreatic carcinogenesis. Pancreatology 2008, 8, 110–125. [Google Scholar] [CrossRef] [PubMed]
- Beuran, M.; Negoi, I.; Paun, S.; Ion, A.D.; Bleotu, C.; Negoi, R.I.; Hostiuc, S. The epithelial to mesenchymal transition in pancreatic cancer: A systematic review. Pancreatology 2015, 15, 217–225. [Google Scholar] [CrossRef] [PubMed]
- Hezel, A.F.; Kimmelman, A.C.; Stanger, B.Z.; Bardeesy, N.; Depinho, R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006, 13, 1218–1249. [Google Scholar] [CrossRef] [PubMed]
- Garcea, G.; Neal, C.P.; Pattenden, C.J.; Steward, W.P.; Berry, D.P. Molecular prognostic markers in pancreatic cancer: A systematic review. Eur. J. Cancer 2005, 41, 2213–2236. [Google Scholar] [CrossRef] [PubMed]
- Neoptolemos, J.P.; Stocken, D.D.; Bassi, C.; Ghaneh, P.; Cunningham, D.; Goldstein, D.; Padbury, R.; Moore, M.J.; Gallinger, S.; Mariette, C.; et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 2010, 304, 1073–1081. [Google Scholar] [CrossRef] [PubMed]
- Ramanathan, R.K.; Belani, C.P.; Singh, D.A.; Tanaka, M.; Lenz, H.J.; Yen, Y.; Kindler, H.L.; Iqbal, S.; Longmate, J.; Mack, P.C.; et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother. Pharmacol. 2009, 64, 777–783. [Google Scholar] [CrossRef]
- Moasser, M.M. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26, 6469–6487. [Google Scholar] [CrossRef]
- Adsay, N.V.; Merati, K.; Basturk, O.; Iacpbuzio-Donahue, C.; Levi, E.; Cheng, J.D.; Sarkar, F.H.; Hruban, R.H.; Klimsta, D.S. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: Delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am. J. Surg. Pathol. 2004, 28, 839–848. [Google Scholar] [CrossRef]
- Pignochino, Y.; Sarotto, I.; Peraldo-Neia, C.; Penachioni, J.Y.; Cavalloni, G.; Migliardi, G.; Casorzo, L.; Chiorino, G.; Risio, M.; Bardelli, A.; et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010, 10, 631. [Google Scholar] [CrossRef]
- Gerdes, B.; Wild, A.; Wittenberg, J.; Barth, P.; Ramaswamy, A.; Kersting, M.; Luttges, J.; Klöppel, G.; Bartsch, D.K. Tumor-suppressing pathways in cystic pancreatic tumors. Pancreas 2003, 13, 42–48. [Google Scholar] [CrossRef]
- Roskoski, R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 2014, 79, 34–74. [Google Scholar] [CrossRef] [PubMed]
- Aumayr, K.; Soleiman, A.; Sahora, K.; Schindl, M.; Werba, G.; Schoppmann, S.F.; Birner, P. HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas. Appl. Immunohistochem. Mol. Morphol. 2014, 22, 146–152. [Google Scholar] [CrossRef]
- Larbouret, C.; Robert, B.; Navarro-Teulon, I.; Thèzenas, S.; Ladjemi, M.-Z.; Morisseau, S.; Campigna, E.; Bibeau, F.; Mach, J.P.; Pèlegrin, A.; et al. In vivo Therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin. Cancer Res. 2007, 13, 3356–3362. [Google Scholar] [CrossRef] [PubMed]
- Ben-Kasus, T.; Schechter, B.; Lavi, S.; Yarden, Y.; Sela, M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc. Natl. Acad. Sci. USA 2009, 106, 3294–3299. [Google Scholar] [CrossRef] [PubMed]
- Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341–354. [Google Scholar] [CrossRef]
- Marks, E.I.; Yee, N.S. Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J. Gastroenterol. 2016, 22, 1335–1347. [Google Scholar] [CrossRef]
- Mendelsohn, J.; Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19, 6550–6565. [Google Scholar] [CrossRef]
- Chow, N.H.; Huang, S.M.; Chan, S.H.; Mo, L.R.; Hwang, M.H.; Su, W.C. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer. Res. 1995, 15, 1055–1059. [Google Scholar] [PubMed]
- Collier, J.D.; Guo, K.; Mathew, J.; May, F.E.; Bennett, M.K.; Corbett, I.P.; Bassendine, M.F.; Burt, A.D. c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J. Hepatol. 1992, 14, 377–380. [Google Scholar] [CrossRef] [PubMed]
- Bittoni, A.; Mandolesi, A.; Andrikou, K.; Santoni, M.; Alfonsi, S.; Lanese, A.; Loretelli, C.; Pellei, C.; Piva, F.; Scarpelli, M.; et al. HER family Receptor Expression and Prognosis in Pancreatic Cancer. Int. J. Biol. Markers 2015, 30, 327–332. [Google Scholar] [CrossRef] [PubMed]
- Nicola, F.; Silvano, B. HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. World J. Gastroenterol. 2016, 22, 7926–7937. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Zhao, H.; Gu, J.; Zheng, L. Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): A meta-analysis. World J. Surg. Oncol. 2016, 14, 38. [Google Scholar] [CrossRef] [PubMed]
- Elebro, J.; Heby, M.; Warfvinge, C.F.; Nodin, B.; Eberhard, J.; Jirstrom, K. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. PLoS ONE 2016, 11, 0153533. [Google Scholar] [CrossRef] [PubMed]
- Galdy, S.; Lamarca, A.; McNamara, M.G.; Hubner, R.A.; Cella, C.A.; Fazio, N.; Valle, J.W. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target? Cancer Metastasis Rev. 2017, 36, 141–157. [Google Scholar] [CrossRef] [PubMed]
- Majid, M.; Fatemeh, E.; Sepideh, H.; Hassan, Y.; Sepehr, J.; Vasimeh, V.; Alishahi, Z.; Mousavipak, S.H.; Bashash, D.; Dehpour, A.R.; et al. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. Cell Oncol. 2019, 42, 491–504. [Google Scholar] [CrossRef]
- Assenat, E.; Mineur, L.; Mollevi, C.; Lopez-Crapez, E.; Lombard-Bohas, C.; Samalin, E.; Portales, F.; Walter, T.; de Forges, H.; Dupuy, M.; et al. Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). Int. J. Cancer 2020, 1, 682–691. [Google Scholar] [CrossRef] [PubMed]
- Khan, T.; Seddon, A.M.; Dalgleish, A.G.; Khelwatty, S.; Ioannou, N.; Mudan, S.; Modjtahedi, H. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer. Oncol. Rep. 2020, 44, 2581–2594. [Google Scholar] [CrossRef]
- Rabia, E.; Garambois, V.; Hubert, J.; Bruciamacchie, M.; Pirot, N.; Delpech, H.; Broyon, M.; Theillet, C.; Colombo, P.E.; Vie, N.; et al. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. Mabs 2021, 13, 1914883. [Google Scholar] [CrossRef]
- Marinovic, S.; Berkovic, M.C.; Zjacic-Rotkvic, V.; Kapitanovic, S. Analysis of polymorphisms in EGF, EGFR and HER2 genes in pancreatic neuroendocrine tumors (PNETs). Cancer Genet. 2022, 266–267, 44–50. [Google Scholar] [CrossRef]
- Ohba, A.; Morizane, C.; Ueno, M.; Kobayashi, S.; Kawamoto, Y.; Komatsu, Y.; Ikeda, M.; Sasaki, M.; Okano, N.; Furuse, J.; et al. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 2022, 18, 2351–2360. [Google Scholar] [CrossRef] [PubMed]
- de Vries, E.G.E.; Rüschoff, J.; Lolkema, M.; Tabernero, J.; Gianni, L.; Voest, E.; de Groot, D.J.; Castellano, D.; Erb, G.; Naab, J.; et al. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. Cancer Med. 2023, 12, 12071–12083. [Google Scholar] [CrossRef] [PubMed]
- Chou, A.; Waddell, N.; Cowley, M.J.; Gill, A.J.; Chang, D.K.; Patch, A.M.; Nones, K.; Wu, J.; Pinese, M.; Johns, A.L.; et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 2013, 5, 78. [Google Scholar] [CrossRef] [PubMed]
- Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014, 74, 2913–2921. [Google Scholar] [CrossRef]
- Adel, N. Current treatment landscape and emerging therapies for pancreatic cancer. Am. J. Manag. Care 2019, 25, 3–10. [Google Scholar]
- Harder, J.; Ihorst, G.; Heinemann, V.; Hofheinz, R.; Moehler, M.; Buechler, P.; Kloeppel, G.; Röcken, C.; Bitzer, M.; Boeck, S.; et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br. J. Cancer 2012, 106, 1033–1038. [Google Scholar] [CrossRef] [PubMed]
- Wiggers, J.K.; Ruys, A.T.; Groot Koerkamp, B.; Beuers, U.; ten Kate, F.J.; van Gulik, T.M. Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2014, 29, 1582–1594. [Google Scholar] [CrossRef]
- Tsiambas, E.; Karameris, A.; Dervenis, C.; Lazaris, A.C.; Giannakou, N.; Gerontopoulos, K.; Patsouris, E. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: A comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP 2006, 7, 283–294. [Google Scholar]
- Wood, E.R.; Truesdale, A.T.; McDonald, O.B.; Yuan, D.; Hassell, A.; Dickerson, S.H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64, 6652–6659. [Google Scholar] [CrossRef]
- Tsurutani, J.; Iwata, H.; Krop, I.; Jänne, P.A.; Doi, T.; Takahashi, S.; Park, H.; Redfern, C.; Tamura, K.; Wise-Draper, T.M.; et al. Targeting HER2 with trastuzumab deruxtecan: A dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov. 2020, 10, 688–701. [Google Scholar] [CrossRef] [PubMed]
- Pelzer, U.; Opitz, B.; Deutschinoff, G.; Stauch, M.; Reitzig, P.C.; Hahnfeld, S.; Müller, L.; Grunewald, M.; Stieler, J.M.; Sinn, M.; et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: Outcomes from the CONKO-004 trial. J. Clin. Oncol. 2015, 33, 2028–2034. [Google Scholar] [CrossRef] [PubMed]
- Valsecchi, M.E.; McDonald, M.; Brody, J.R.; Hyslop, T.; Freydin, B.; Yeo, C.J.; Solomides, C.; Peiper, S.C.; Witkiewicz, A.K. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer 2012, 118, 3484–3493. [Google Scholar] [CrossRef] [PubMed]
- Pryczynicz, A.; Guzińska-Ustymowicz, K.; Czyzewska, J.; Kemona, A. Expression of epidermal growth factors and apoptosis markers in pancreatic ductal adenocarcinoma. Folia Histochem. Cytobiol. 2009, 47, 667–671. [Google Scholar] [CrossRef] [PubMed]
- Cardin, D.B.; Goff, L.W.; Chan, E.; Whisenant, J.G.; Dan Ayers, G.; Takebe, N.; Arlinghaus, L.R.; Yankeelov, T.E.; Berlin, J.; Merchant, N. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: Phase I results: A phase I clinical trial. Investig. New. Drugs 2018, 36, 442–450. [Google Scholar] [CrossRef]
- Nagarkar, R.; Patil, D.; Limaye, S.; Devhare, P.; Ghaisas, A.; Srivastava, N.; Apurwa, S.; Patil, S.; John, J.; Raazi, Z.; et al. Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy. Oncotarget 2020, 11, 4195–4200. [Google Scholar] [CrossRef]
Authors | Year of Publication | Title | Aim of the Study |
---|---|---|---|
Bittoni et al. [23] | 2015 | HER family Receptor Expression and Prognosis in Pancreatic Cancer | Identifying HER family overexpression in PDAC |
Nicola et al. [24] | 2016 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists | Identifying HER2 aberrations and overexpression in periampullary tumors |
Xiaoping et al. [25] | 2016 | Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis | Identifying the prognostic role of HER2 positivity in PDAC |
Elebro et al. [26] | 2016 | Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma | Identifying EGFR, HER2, and HER3 expression and HER2 amplification status in periampullary tumors |
Salvatore et al. [27] | 2017 | HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? | Identifying the HER2 overexpression rate in BTC |
Majid et al. [28] | 2019 | The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells | Evaluating dacomitinib’s effect upon EGFR, HER2, and HER3 expression in PDAC |
Assenat et al. [29] | 2020 | Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1) | Evaluating survival rate in patients with HER2+ advanced PDAC |
Tanzeel et al. [30] | 2020 | Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer | Identifying cells’ surface expression of various growth factor receptors in PDAC |
Rabia et al. [31] | 2021 | Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models | Identifying and understanding the pathways of the pan-HER antibody family in PDAC |
Marinovic et al. [32] | 2022 | Analysis of polymorphisms in EGF, EGFR and HER2 genes in pancreatic neuroendocrine tumors (PNETs) | Identifying the overexpression of EGF, EGFR, and HER2 receptors in PNET |
Akihiro et al. [33] | 2022 | Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial | Identifying the benefit of trastuzumab deruxtecan on the ORR in HER2-positive BTC |
de Vries et al. [34] | 2023 | Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma | Identifying the relationship between biomarkers and tumor response to treatment in PDAC and BTC |
Authors | Pathways and Drugs Used | Number of Patients | Detection Method |
---|---|---|---|
Bittoni et al. [23] | N.A. | 91 PDAC | IHC 1+ |
Nicola et al. [24] | Topoisomerase inhibition Trastuzumab deruxtecan + Capecitabine | 17 PDAC | IHC2+ and 3+ ISH 2+ and 3+ |
Xiaoping et al. [25] | N.A. | 764 PDAC | ISH 1+ and 2+ |
Elebro et al. [26] | N.A. | 175 PDAC + BTC + AVC | (TMAs) IHC 2+ and 3+ |
Salvatore et al. [27] | N.A. | 920 BTC 303 AVC | IHC2+ and 3+ ISH 2+ and 3+ |
Majid et al. [28] | ERBB inhibition Dacomitinib + lapatinib | 96 PDAC | MTT assay |
Assenat et al. [29] | Tyrosine kinase inhibition Erlotinib + Trastuzumab + Gemcitabine | 62 PDAC | IHC 2+ and 3+ |
Tanzeel et al. [30] | Tyrosine kinase inhibition Dinaciclib + afatinib + dasatinib | 96 PDAC | Flow cytometry (fluorescence intensity MFI) |
Rabia et al. [31] | Pan-HER Inhibition | 45 PDAC (Gemcitabine-resistant cells) | IHC 2+ and 3+ |
Marinovic et al. [32] | N.A. | 68 PNETs | SNP genotyping |
Akihiro et al. [33] | Topoisomerase inhibition Trastuzumab deruxtecan | 32 BTC | IHC 2+ and 3+ ISH 2+ and 3+ |
de Vries et al. [34] | Topoisomerase inhibition Trastuzumab emtansine | 133 PDAC | IHC 3+ |
82 BTC |
Title | Immunotherapy vs. Chemotherapy in HER2+ |
---|---|
Bittoni et al. [23] | Trastuzumab + Capecitabine > Capecitabine alone in PDAC |
Nicola et al. [24] | Trastuzumab-emtansine + Gemcitabine > Gemcitabine alone in BTC and metastatic digestive tumors |
Xiaoping et al. [25] | Trastuzumab + gemcitabine > chemotherapy + gemcitabine in PDAC |
Elebro et al. [26] | Erlotinib + gemcitabine > chemotherapy + gemcitabine in BTC and PDAC |
Salvatore et al. [27] | Pertuzumab + trastuzumab/pertuzumab emtansine + Gemcitabine > Cisplatin + gemcitabine in BTC |
Majid et al. [28] | Afatinib > erlotinib in PDAC |
Assenat et al. [29] | FOLFIRINOX > Trastuzumab + erlotinib + Gemcitabine > Nab-paclitaxel + gemcitabine in PDAC |
Tanzeel et al. [30] | Afatinib + IGF-IR/afatinib + dasatinib/dasatinib + gemcitabine > chemotherapy + gemcitabine in PDAC |
Rabia et al. [31] | Cetuximab + trastuzumab + pertuzumab > chemotherapy + gemcitabine in PDAC |
Marinovic et al. [32] | Cetuximab + trastuzumab > Erlotinib + trastuzumab in PNET |
Akihiro et al. [33] | Trastuzumab deruxtecan > FOLFOX/FOLFIRI in BTC |
de Vries et al. [34] | Trastuzumab deruxtecan/trastuzumab duocarmazine + chemotherapy > chemotherapy alone in BTC |
Author | HER2 Overexpression According to Histopathological Type | Target Agents |
---|---|---|
Bittoni et al. [23] | 1.1% in PDAC | Trastuzumab |
Nicola et al. [24] | 5–76% overexpression and 1–8% amplification in BTC 0–50% overexpression and 2–29% amplification in PDAC | Trastuzumab, Pertuzumab, Lapatinib, Neratinib, Afatinib |
Xiaoping et al. [25] | 2.1–23.8% overexpression and 16% amplification in PDAC | Trastuzumab |
Elebro et al. [26] | 11% in PDAC 7% in BTC 15% in AVC | Erlotinib |
Salvatore et al. [27] | 19.9% in PDAC 17.4% in BTC 27.9% in AVC | Trastuzumab, Pertuzumab |
Majid et al. [28] | 16% in resectable PDAC 26% in metastatic PDAC | Dacomitinib |
Assenat et al. [29] | 58.3% in PDAC | Trastuzumab, Erlotinib |
Tanzeel et al. [30] | 26.27% in PDAC | Dinaciclib, Afatinib, IGF-IR |
Rabia et al. [31] | 24% in PDAC with 11% positive for combination of EGFR + HER2 + HER3 | Trastuzumab, Lapatinib, U3-1287 |
Marinovic et al. [32] | 37.9% in nonfunctional PNET 36.11% in functional PNET 42.31% in insulinomas | Trastuzumab, Cetuximab |
Akihiro et al. [33] | 10–20% in BTC | Trastuzumab Deruxtecan |
de Vries et al. [34] | 6.3% in PDAC 7.9% in BTC | Trastuzumab Duocarmazine |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bodea, I.C.; Ciocan, A.; Zaharie, F.V.; Bodea, R.; Graur, F.; Ursu, Ș.; Ciocan, R.A.; Al Hajjar, N. HER2 Overexpression in Periampullary Tumors According to Anatomical and Histological Classification—A Systematic Review. J. Pers. Med. 2024, 14, 463. https://doi.org/10.3390/jpm14050463
Bodea IC, Ciocan A, Zaharie FV, Bodea R, Graur F, Ursu Ș, Ciocan RA, Al Hajjar N. HER2 Overexpression in Periampullary Tumors According to Anatomical and Histological Classification—A Systematic Review. Journal of Personalized Medicine. 2024; 14(5):463. https://doi.org/10.3390/jpm14050463
Chicago/Turabian StyleBodea, Ioan Cătălin, Andra Ciocan, Florin Vasile Zaharie, Raluca Bodea, Florin Graur, Ștefan Ursu, Răzvan Alexandru Ciocan, and Nadim Al Hajjar. 2024. "HER2 Overexpression in Periampullary Tumors According to Anatomical and Histological Classification—A Systematic Review" Journal of Personalized Medicine 14, no. 5: 463. https://doi.org/10.3390/jpm14050463